What is HC Wainwright’s Estimate for ACHV Q1 Earnings?

Achieve Life Sciences, Inc. (NASDAQ:ACHV) – Analysts at HC Wainwright issued their Q1 2026 EPS estimates for shares of Achieve Life Sciences in a research note issued on Wednesday, March 25th. HC Wainwright analyst B. Folkes expects that the biopharmaceutical company will earn ($0.30) per share for the quarter. HC Wainwright currently has a “Buy” rating and a $12.00 target price on the stock. The consensus estimate for Achieve Life Sciences’ current full-year earnings is ($1.17) per share. HC Wainwright also issued estimates for Achieve Life Sciences’ Q2 2026 earnings at ($0.33) EPS, Q3 2026 earnings at ($0.32) EPS and Q4 2026 earnings at ($0.33) EPS.

Separately, Weiss Ratings reiterated a “sell (d-)” rating on shares of Achieve Life Sciences in a research note on Monday, December 29th. One research analyst has rated the stock with a Strong Buy rating, three have given a Buy rating and one has assigned a Sell rating to the company. According to data from MarketBeat, Achieve Life Sciences has an average rating of “Moderate Buy” and a consensus price target of $15.50.

Achieve Life Sciences Stock Performance

NASDAQ:ACHV opened at $2.65 on Thursday. The firm has a market capitalization of $141.07 million, a PE ratio of -2.04 and a beta of 1.81. The company has a quick ratio of 5.14, a current ratio of 4.39 and a debt-to-equity ratio of 0.52. Achieve Life Sciences has a 12-month low of $1.84 and a 12-month high of $6.03. The firm has a 50-day moving average price of $4.31 and a 200 day moving average price of $4.29.

Achieve Life Sciences (NASDAQ:ACHV) last issued its earnings results on Tuesday, March 24th. The biopharmaceutical company reported ($0.28) earnings per share for the quarter, missing the consensus estimate of ($0.27) by ($0.01).

Institutional Investors Weigh In On Achieve Life Sciences

Several large investors have recently made changes to their positions in ACHV. AQR Capital Management LLC acquired a new stake in shares of Achieve Life Sciences during the 1st quarter worth about $32,000. Next Capital Management LLC acquired a new position in Achieve Life Sciences in the third quarter valued at about $51,000. Sender Co & Partners Inc. bought a new stake in Achieve Life Sciences during the second quarter worth about $56,000. OneDigital Investment Advisors LLC bought a new stake in Achieve Life Sciences during the third quarter worth about $63,000. Finally, Magnolia Capital Advisors LLC acquired a new stake in shares of Achieve Life Sciences during the fourth quarter worth approximately $64,000. Institutional investors own 33.52% of the company’s stock.

Achieve Life Sciences News Summary

Here are the key news stories impacting Achieve Life Sciences this week:

• Positive Sentiment: HC Wainwright reiterated a Buy rating and $12 target while materially boosting long‑range EPS forecasts (FY2029 and FY2030 upgrades), signaling confidence in ACHV’s longer‑term commercial potential. Achieve Life Sciences (NASDAQ:ACHV) Earns Buy Rating from HC Wainwright
• Positive Sentiment: A peer‑reviewed publication linked cytisinicline’s receptor profile to low nausea and favorable tolerability, a clinical differentiator that could support uptake if approved. Publication in Nicotine & Tobacco Research
• Positive Sentiment: Analysts and commentators are highlighting the upcoming PDUFA (June 20, 2026) and planned Phase 3 vaping cessation trial (ORCA‑V2 in 1H 2026) as major value catalysts toward a possible 1H‑2027 commercial launch if approved. Achieve Life Sciences: Maintaining ‘Buy’ On Upcoming PDUFA…
• Positive Sentiment: Unusually large retail/institutional activity in call options suggests speculative bullish positioning ahead of the PDUFA and other near‑term catalysts. Investors Purchase Large Volume of Call Options on Achieve Life Sciences
• Neutral Sentiment: HC Wainwright also updated quarter‑by‑quarter 2026 EPS estimates (small quarterly losses expected) while keeping the Buy stance — important for modeling near‑term cash needs but not a directional change to the thesis. MarketBeat ACHV coverage
• Neutral Sentiment: The company’s Q4 2025 transcript and summary show a modest EPS miss and operational detail; useful for context on execution but not a game‑changer versus the upcoming FDA decision. Q4 2025 earnings call transcript Q4 2025 Earnings Call Summary
• Negative Sentiment: Mixed analyst revisions include downgrades to mid‑term EPS (HC Wainwright trimmed FY2027 and FY2028; Zacks cut FY2026/FY2027), which raises uncertainty on near‑term profitability and could pressure the stock ahead of the PDUFA. Market analyst estimate changes

Achieve Life Sciences Company Profile

Achieve Life Sciences, Inc (NASDAQ: ACHV) is a clinical-stage biotechnology company dedicated to the development and commercialization of cytisinicline, a plant-derived alkaloid for smoking cessation. The company’s mission is to offer a novel, evidence-based therapy that addresses the global need for effective and well-tolerated smoking cessation options. Achieve focuses its efforts on advancing the clinical profile of cytisinicline through rigorous development programs and regulatory engagement.

Cytisinicline (formerly marketed as Tabex® in Europe) acts as a nicotinic acetylcholine receptor partial agonist, helping reduce withdrawal symptoms and nicotine cravings.